CSAPA clients - situation in 2014 and changes since 2007

 

eftacpw6.jpg

Tendances n° 110, OFDT, 8 p.
June 2016

Although the treatment and prevention centres for addiction (CSAPA) are primarily an instrument for treating addictions, whether psychoactive substance use (alcohol, illegal drugs) or non-substance addictions, they also represent a platform for observing individuals facing these problems, through  a national survey (Common Data Collection on Addictions and Treatments – RECAP) and common activity reports.
This issue of Tendances focuses on the description, based on these two sources, of the characteristics of CSAPA clients in 2014, and the changes since 2007. In the years from 2007 to 2014, the CSAPA underwent major changes related to the expansion and redefinition of their missions. The number of clients increased by 10% between 2010 and 2014, and most certainly in a higher proportion between 2007 and 2014.
The most striking change occurring during this period is the reduction in the number of individuals describing heroin as the primary drug and the increase in the number of cannabis users.

Author : Christophe Palle

Download the PDF file (515 Ko)

 

 

 

 

 

 

 

 

Drugs in Europe


2021 EMCDDA European Drug Report

COVID-19
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2021

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.